Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.58 USD
Change Today -0.22 / -5.79%
Volume 584.9K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

coronado biosciences inc (CNDO) Snapshot

Open
$3.81
Previous Close
$3.80
Day High
$3.98
Day Low
$3.53
52 Week High
03/19/15 - $5.35
52 Week Low
08/8/14 - $1.45
Market Cap
166.5M
Average Volume 10 Days
3.5M
EPS TTM
$-0.54
Shares Outstanding
46.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORONADO BIOSCIENCES INC (CNDO)

coronado biosciences inc (CNDO) Related Bloomberg News

View More Bloomberg News

coronado biosciences inc (CNDO) Related Businessweek News

No Related Businessweek News Found

coronado biosciences inc (CNDO) Details

Coronado Biosciences, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. The company has strategic alliances and commercial agreements with Ovamed GmbHp; Dr. Falk Pharma GmbH; and Freie Universität Berlin. Coronado Biosciences, Inc. was founded in 2006 and is based in Burlington, Massachusetts.

16 Employees
Last Reported Date: 03/16/15
Founded in 2006

coronado biosciences inc (CNDO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $980.0
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $540.8K
Senior Vice President of Biologics Operations
Total Annual Compensation: $250.3K
Compensation as of Fiscal Year 2013.

coronado biosciences inc (CNDO) Key Developments

Coronado Biosciences and City of Hope Hospital Form New Company, Mustang Therapeutics

Coronado Biosciences said that it has formed a new company, named Mustang Therapeutics, in partnership with City of Hope hospital near Los Angeles. The new enterprise will focus on the clinical development and commercialization of proprietary chimeric antigen receptor technology to fight refractory cancers, that is cancers unresponsive to surgery or chemotherapy. CNDO valued the new business formation in excess of $40 million in terms of up-front and milestone payments to City of Hope, and projected enrollment in cancer-treating human clinical trials at the City of Hope this year.

Coronado Biosciences, Inc. Announces Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Coronado Biosciences, Inc. announced consolidated financial results for the fourth quarter and year ended December 31, 2014. The company reported net loss attributed to common stockholders of $3.7 million, or $0.10 per basic and diluted share, for the fourth quarter of 2014 compared to net loss of $9.8 million, or $0.27 per basic and diluted share, for the fourth quarter of 2013. Loss from operations was $4,961,000 compared to $9,524,000 a year ago. For the year ended December 31, 2014, the company reported net loss attributed to common stockholders of $20.4 million, or $0.56 per basic and diluted share, compared to a net loss of $37.2 million, or $1.22 per basic and diluted share, for 2013. Loss from operations was $20,652,000 compared to $35,780,000 a year ago.

Coronado Biosciences, Inc. Announces Formation of New Subsidiary Company, Checkpoint Therapeutics; Appoints Wayne Marasco to its Scientific Advisory Board

Coronado Biosciences, Inc. announced the formation of a new subsidiary company, Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber). Dr. Marasco will chair the Scientific Advisory Board of the company. Under the terms of the agreement, Checkpoint will pay Dana-Farber an up-front licensing fee in addition to development and sales-based milestone payments and royalties on net sales. The portfolio of antibodies licensed from Dana-Farber includes antibodies targeting PD-L1, GITR and CAIX. Checkpoint plans to develop these novel immuno-oncology and checkpoint inhibitor antibodies on their own and in combination with each other, as data suggests that combinations of these targets can work synergistically together. Clinical trials are expected to start in the second half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNDO:US $3.58 USD -0.22

CNDO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CNDO.
View Industry Companies
 

Industry Analysis

CNDO

Industry Average

Valuation CNDO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORONADO BIOSCIENCES INC, please visit www.coronadobiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.